Wednesday, 30 March 2011 01:30
Neoprobe Corporation is the only company to optimize radiotracers and gamma detection hardware concurrently, providing tremendous growth opportunity. Neoprobe have been making remarkable strides within their financial and pipeline. In fiscal year 2010, reported revenue increased 12% and gross profit were up 17% compared to fiscal year 2009. The company holds approximately $6.4M in cash with no debt. In February a successful pre-IND meeting with the U.S. Food and Drug Administration re-initia...


